- 中国科学论文统计源期刊
- 中国科技核心期刊
- 美国化学文摘(CA)来源期刊
- 日本科学技术振兴机构数据库(JST)
临床输血与检验 ›› 2023, Vol. 25 ›› Issue (2): 149-162.DOI: 10.3969/j.issn.1671-2587.2023.02.001
• 专家共识 • 下一篇
中国输血协会临床输血管理学专业委员会
收稿日期:2023-03-10
发布日期:2023-04-25
通讯作者:
李志强,男,主任医师,硕士研究生导师,从事血液病学诊治与输血医学研究,（E-mail）kcb039@126.com。基金资助:
Received:2023-03-10
Published:2023-04-25
摘要： 为确保使有限的血液资源,合理应用于重型和危重型COVID-19患者救治,中国输血协会临床输血管理学专业委员会结合国内外临床研究成果,召集了临床输血、重症医学、感染病学、呼吸病学、血液病学、药学等领域的专家共同制定了此专家共识,以期能够规范重型和危重型COVID-19患者血液和血液生物制品输注的适应证和使用过程相关事项,提高患者治愈率,减少死亡率。
中图分类号:
中国输血协会临床输血管理学专业委员会. 重型和危重型COVID-19患者血液成分安全输注专家共识*[J]. 临床输血与检验, 2023, 25(2): 149-162.
| [1] 王吉耀. 论《临床实践指南》/《专家共识》中证据的分级和推荐标准[J].肝脏,2015,20(4):267-268. [2] GUYATT G H,OXMAN A D,VIST G E,et al.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ,2008,336(7650):924-926. [3] BROŻEK J L,AKL E A,ALONSO-COELLO P,et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines[J].Allergy,2009,64(5):669-677. [4] CHILAMAKURI R,AGARWAL S.COVID-19:characteristics and therapeutics[J].Cells,2021,10(2):206. [5] 中华医学会呼吸病学分会,中国医师协会呼吸医师分会,王辰,等.中国成人2019冠状病毒病的诊治与防控指南[J].中华医学杂志,2021,101(18):1293-1356. [6] JACKSON C B,FARZAN M,CHEN B,et al.Mechanisms of SARS-CoV-2 entry into cells[J].Nat Rev Mol Cell Biol,2022,23(1):3-20. [7] V'KOVSKI P,KRATZEL A,STEINER S,et al.Coronavirus biology and replication:implications for SARS-CoV-2[J].Nat Rev Microbiol,2021,19(3):155-170. [8] MEYEROWITZ E A,RICHTERMAN A,GANDHI R T,et al.Transmission of SARS-CoV-2:a review of viral,host,and environmental factors[J].Ann Intern Med,2021,174(1):69-79. [9] GHOSH N,NANDI S M,SAHA I.A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein[J].Int Immunopharmacol,2022,105:108565. [10] BONAVENTURA A,VECCHIÉ A,DAGNA L,et al.Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19[J].Nat Rev Immunol,2021,21(5):319-329. [11] WANG Y H,PERLMAN S.COVID-19:inflammatory profile[J].Annu Rev Med,2022,73:65-80. [12] HADID T,KAFRI Z,AL-KATIB A.Coagulation and anticoagulation in COVID-19[J].Blood Rev,2021,47:100761. [13] BIRNHUBER A,FLIEßER E,GORKIEWICZ G,et al.Between inflammation and thrombosis:endothelial cells in COVID-19[J].Eur Respir J,2021,58(3):2100377. [14] QIN Z N,LIU F M,BLAIR R,et al.Endothelial cell infection and dysfunction,immune activation in severe COVID-19[J].Theranostics,2021,11(16):8076-8091. [15] SMADJA D M,MENTZER S J,FONTENAY M,et al.COVID-19 is a systemic vascular hemopathy:insight for mechanistic and clinical aspects[J].Angiogenesis,2021,24(4):755-788. [16] KAUR S,SINGH A,KAUR J,et al.Upregulation of cytokine signalling in platelets increases risk of thrombophilia in severe COVID-19 patients[J].Blood Cells Mol Dis,2022,94:102653. [17] BARRETT T J,BILALOGLU S,CORNWELL M,et al.Platelets contribute to disease severity in COVID-19[J].J Thromb Haemost,2021,19(12):3139-3153. [18] SHAO Y,SAREDY J,XU K M,et al.Endothelial immunity trained by coronavirus infections,DAMP stimulations and regulated by anti-oxidant NRF2 may contribute to inflammations,myelopoiesis,COVID-19 cytokine storms and thromboembolism[J].Front Immunol,2021,12:653110. [19] GÓMEZ-MESA J E,GALINDO-CORAL S,MONTES M C,et al.Thrombosis and coagulopathy in COVID-19[J].Curr Probl Cardiol,2021,46(3):100742. [20] 国家卫生健康委员会.新型冠状病毒感染诊疗方案(试行第十版)[EB/OL].(2023-01-06) http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml. [21] ELAHI S.Hematopoietic responses to SARS-CoV-2 infection[J].Cell Mol Life Sci,2022,79(3):187. [22] BORCZUK A C,YANTISS R K.The pathogenesis of coronavirus-19 disease[J].J Biomed Sci,2022,29(1):87. [23] LLITJOS J F,BREDIN S,LASCARROU J B,et al.Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients:a multicentre retrospective cohort study[J].Ann Intensive Care,2021,11(1):20. [24] RAMADORI G.Albumin infusion in critically ill COVID-19 patients:hemodilution and anticoagulation[J].Int J Mol Sci,2021,22(13):7126. [25] AHMAD F,KANNAN M,ANSARI A W.Role of SARS-CoV-2-induced cytokines and growth factors in coagulopathy and thromboembolism[J].Cytokine Growth Factor Rev,2022,63:58-68. [26] D'ARDES D,BOCCATONDA A,COCCO G,et al.Impaired coagulation,liver dysfunction and COVID-19:discovering an intriguing relationship[J].World J Gastroenterol,2022,28(11):1102-1112. [27] DELOREY T M,ZIEGLER C G K,HEIMBERG G,et al.COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets[J].Nature,2021,595(7865):107-113. [28] GUAN W J,NI Z Y,HU Y,et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med,2020,382(18):1708-1720. [29] PUELLES V G,LÜTGEHETMANN M,LINDENMEYER M T,et al.Multiorgan and renal tropism of SARS-CoV-2[J].N Engl J Med,2020,383(6):590-592. [30] HUANG C L,WANG Y M,LI X W,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506. [31] XU Z,SHI L,WANG Y J,et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].Lancet Respir Med,2020,8(4):420-422. [32] AL-NUMAIR N S,ALYOUNES B,AL-SAUD H,et al.Clinical characteristics,risk factors,and rate of severity of a nationwide COVID-19 Saudi cohort[J].Saudi J Biol Sci,2022,29(7):103315. [33] GENG M J,WANG L P,REN X,et al.Risk factors for developing severe COVID-19 in China:an analysis of disease surveillance data[J].Infect Dis Poverty,2021,10(1):48. [34] 中国研究型医院学会危重医学专业委员会, 中国研究型医院学会危重医学专委会青年委员会.重型和危重型新型冠状病毒肺炎诊断和治疗专家共识(修订版)[J] .中华危重病急救医学,2020,32(03): 269-274. [35] CHEN N S,ZHOU M,DONG X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507-513. [36] YANG X B,YU Y,XU J Q,et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,China:a single-centered,retrospective,observational study[J].Lancet Respir Med,2020,8(5):475-481. [37] ZHOU F,YU T,DU R H,et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,China:a retrospective cohort study[J].Lancet,2020,395(10229):1054-1062. [38] WANG D W,HU B,HU C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J].JAMA,2020,323(11):1061-1069. [39] Cheng LL, Guan WJ, Duan CY, et al.Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial[J].JAMA Intern Med.2021,181(1):71-78. [40] WEISBERG S P,CONNORS T J,ZHU Y,et al.Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum[J].Nat Immunol,2021,22(1):25-31. [41] ZHANG J,LIN H,YE B W,et al.One-year sustained cellular and humoral immunities in coronavirus disease 2019 (COVID-19) convalescents[J].Clin Infect Dis,2022,75(1):e1072-e1081. [42] KANEKO S,NUKUI Y,ARASHIRO T,et al.Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort[J].J Med Virol,2021,93(1):569-572. [43] LEI Q,LI Y,HOU H Y,et al.Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections[J].Allergy,2021,76(2):551-561. [44] VALDEZ-CRUZ N A,GARCÍA-HERNÁNDEZ E,ESPITIA C,et al.Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment[J].Microb Cell Fact,2021,20(1):88. [45] BRUCHFELD A.The COVID-19 pandemic:consequences for nephrology[J].Nat Rev Nephrol,2021,17(2):81-82. [46] SAGOSCHEN I,KELLER K,WILD J,et al.Case fatality of hospitalized patients with COVID-19 infection suffering from acute respiratory distress syndrome in Germany[J].Viruses,2022,14(11):2515. [47] AMIRFAKHRYAN H,SAFARI F.Outbreak of SARS-CoV2:Pathogenesis of infection and cardiovascular involvement[J].Hellenic J Cardiol,2021,62(1):13-23. [48] LIAKINA V,STUNDIENE I,MILAKNYTE G,et al.Effects of COVID-19 on the liver:the experience of a single center[J].World J Gastroenterol,2022,28(39):5735-5749. [49] ABRAHAM R S,MARSHALL J M,KUEHN H S,et al.Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant[J].J Allergy Clin Immunol,2021,147(2):532-544.e1. [50] RIAL-CRESTELO D,BISBAL O,FONT R,et al.Incidence and severity of SARS-CoV-2 infection in HIV-infected individuals during the first year of the pandemic[J].JAIDS J Acquir Immune Defic Syndr,2022,89(5):511-518. [51] WANG Z T,CHAN E C Y.Physiologically-based pharmacokinetic modeling-guided dose management of oral anticoagulants when initiating nirmatrelvir/ritonavir (paxlovid) for COVID-19 treatment[J].Clin Pharmacol Ther,2022,112(4):803-807. [52] DROŻDŻAL S,ROSIK J,LECHOWICZ K,et al.An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment[J].Drug Resist Updat,2021,59:100794. [53] HO W S,ZHANG R R,TAN Y L,et al.COVID-19 and the promise of small molecule therapeutics:are there lessons to be learnt?[J].Pharmacol Res,2022,179:106201. [54] BRADY D K,GURIJALA A R,HUANG L Y,et al.A guide to COVID-19 antiviral therapeutics:a summary and perspective of the antiviral weapons against SARS-CoV-2 infection[J].FEBS J,2022. [55] YU J J,WANG Y,RAGUENEAU-MAJLESSI I.Strong pharmacokinetic drug-drug interactions with drugs approved by the US food and drug administration in 2021:mechanisms and clinical implications[J].Clin Ther,2022,44(11):1536-1544. [56] ŞIMŞEK-YAVUZ S,ÇELIKYURT F I K.An update of anti-viral treatment of COVID-19[J].Turk J Med Sci,2021,51(SI-1):3372-3390. [57] BARBARO RYAN P,GRAEME M,BOONSTRA PHILIP S,et al.Extracorporeal membrane oxygenation for COVID-19:evolving outcomes from the international Extracorporeal Life Support Organization Registry[J].Lancet,2021,398(10307):1230-1238. [58] YANG S,WILLIAMS B,KACZOROWSKI D,et al.Overt disseminated intravascular coagulation with severe hypofibrinogenemia during veno-venous extracorporeal membrane oxygenation[J].J Extra Corpor Technol,2022,54(2):148-152. [59] ALHUMAID S,AL MUTAIR A,ALGHAZAL H A,et al.Extracorporeal membrane oxygenation support for SARS-CoV-2:a multi-centered,prospective,observational study in critically ill 92 patients in Saudi Arabia[J].Eur J Med Res,2021,26(1):141. [60] 中国医师协会体外生命支持专业委员会.成人体外膜氧合循环辅助专家共识[J] .中华医学杂志,2018,98(12): 886-894. [61] 中国医师协会呼吸医师分会危重症医学专业委员会,中华医学会呼吸病学分会危重症医学学组.体外膜式氧合治疗成人重症呼吸衰竭推荐意见[J].中华结核和呼吸杂志,2019,42(9):660-684. [62] FELDHAUS D,BRODIE D,LEMAITRE P,et al.The evolution of the use of extracorporeal membrane oxygenation in respiratory failure[J].Membranes (Basel),2021,11(7):491. [63] DOYLE A J,RICHARDSON C,SANDERSON B,et al.Restrictive transfusion practice in adults receiving venovenous extracorporeal membrane oxygenation:a single-center experience[J].Crit Care Explor,2020,2(1):e0077. [64] 国家卫生健康委员会.内科输血:WS/T622-2018[S/OL].(2018-09-26).http://www.nhc.gov.cn/wjw/s9493/201901/def2474a4e194ea2877acf94f552147c.shtml. [65] DOYLE A J,DANAEE A,FURTADO C I,et al.Blood component use in critical care in patients with COVID-19 infection:a single-centre experience[J].Br J Haematol,2020,191(3):382-385. [66] GALLO MARIN B,AGHAGOLI G,LAVINE K,et al.Predictors of COVID-19 severity:a literature review[J].Rev Med Virol,2021,31(1):1-10. [67] COLOMBIER S,GROSS A,SCHNEIDER A,et al.Hemodynamic oxygenator exchange-related effects during veno-venous extracorporeal membrane oxygenation for the treatment of acute SARS-CoV-2 respiratory distress syndrome[J].Perfusion,2023,38(2):425-427. [68] FLAUMENHAFT R,ENJYOJI K,SCHMAIER A A.Vasculopathy in COVID-19[J].Blood,2022,140(3):222-235. [69] BÖSMÜLLER H,MATTER M,FEND F,et al.The pulmonary pathology of COVID-19[J].Virchows Arch,2021,478(1):137-150. [70] TAJBAKHSH A,GHEIBI HAYAT S M,TAGHIZADEH H,et al.COVID-19 and cardiac injury:clinical manifestations,biomarkers,mechanisms,diagnosis,treatment,and follow up[J].Expert Rev Anti Infect Ther,2021,19(3):345-357. [71] BERZUINI A,BIANCO C,PACCAPELO C,et al.Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19[J].Blood,2020,136(6):766-768. [72] MATSUURA H,FUJII S,MATSUI Y,et al.An association between a positive direct antiglobulin test and HLA-DR12 in COVID-19[J].Ann Hematol,2022,101(9):1959-1969. [73] NAWAZ H,CHOUDHRY A,MORSE W J,et al.Do admitted COVID-19-positive patients on anticoagulation therapy have a reduced hospital stay and disease severity?[J].Cureus,2022,14(3):e23382. [74] S K S R,P A A,B S,et al.Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19:a evidence-based review from six databases[J].Diabetes Metab Syndr Clin Res Rev,2022,16(3):102451. [75] MACLAREN G,COMBES A,BRODIE D.What’s new in ECMO for COVID-19?[J].Intensive Care Med,2021,47(1):107-109. [76] RAMANATHAN K,SHEKAR K,LING R R,et al.Extracorporeal membrane oxygenation for COVID-19:a systematic review and meta-analysis[J].Crit Care,2021,25(1):1-11. [77] BADULAK J,ANTONINI M V,STEAD C M,et al.Extracorporeal membrane oxygenation for COVID-19:updated 2021 guidelines from the extracorporeal life support organization[J].Asaio J,2021,67(5):485-495. [78] WOOL G D,MILLER J L.The impact of COVID-19 disease on platelets and coagulation[J].Pathobiology,2021,88(1):15-27. [79] ASAKURA H,OGAWA H.COVID-19-associated coagulopathy and disseminated intravascular coagulation[J].Int J Hematol,2021,113(1):45-57. [80] BACHLER M,BÖSCH J,STÜRZEL D P,et al.Impaired fibrinolysis in critically ill COVID-19 patients[J].Br J Anaesth,2021,126(3):590-598. [81] COREY K M,OLSON L B,NAQVI I A,et al.Suppression of fibrinolysis and hypercoagulability,severity of hypoxemia,and mortality in COVID-19 patients:a retrospective cohort study[J].Anesthesiology,2022,137(1):67-78. [82] NEETHLING C,CALLIGARO G,MILLER M,et al.The evolution of clot strength in critically-ill COVID-19 patients:a prospective observational thromboelastography study[J].Thromb J,2021,19(1):83. [83] DUJARDIN R W G,GARCIA ROSENBAUM G,KLERCQ T C J,et al.Rotational thromboelastometry in critically ill COVID-19 patients does not predict thrombosis[J].Res Pract Thromb Haemost,2022,6(6):e12798. [84] GUY S,KITCHEN S,HOPKINS B,et al.Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia[J].Int J Lab Hematol,2022,44(2):399-406. [85] SHIUAN E,SHARMA D,ELY E W,et al.Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection[J].J Thromb Thrombolysis,2022,54(2):367-371. [86] CUKER A,AREPALLY G M,CHONG B H,et al.American Society of Hematology 2018 guidelines for management of venous thromboembolism:heparin-induced thrombocytopenia[J].Blood Adv,2018,2(22):3360-3392. [87] FRANCHINI M,FOCOSI D.Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A:a case report and literature update[J].Thromb Res,2023,222:7-11. [88] FAVALORO E J,PASALIC L,LIPPI G.Autoimmune diseases affecting hemostasis:a narrative review[J].Int J Mol Sci,2022,23(23):14715. [89] DEMIRCI U,UMIT E G,OZDEMIR H,et al.Improving care of older patients with hemophilia during COVID-19 pandemic,reducing the risk of venous thrombosis with home exercises[J].Clin Appl Thromb Hemost,2022,28:10760296221087223. [90] MARJOT T,MOON A M,COOK J A,et al.Outcomes following SARS-CoV-2 infection in patients with chronic liver disease:an international registry study[J].J Hepatol,2021,74(3):567-577. [91] LIMON-DE LA ROSA N,CERVANTES-ALVAREZ E,NAVARRO-ALVAREZ N.Increased hepatic expression of SARS-CoV-2 entry points and proinflammatory cytokines in cirrhosis[J].Clin Gastroenterol Hepatol,2022,20(1):239-241.e3. [92] MUÑOZ-MARTÍNEZ S,SAPENA V,FORNER A,et al.Assessing the impact of COVID-19 on liver cancer management (CERO-19)[J].JHEP Rep,2021,3(3):100260. [93] NTELIS S,CHAMP K.Recurrence of thrombotic thrombocytopenic Purpura after vaccination with mRNA-1273 COVID-19 vaccine[J].J Community Hosp Intern Med Perspect,2022,12(4):80-84. [94] FANG F,TSE B,PAVENSKI K.Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection[J].BMJ Case Rep,2022,15(7):e247524. [95] MALGAJ VREČKO M, ALEŠ RIGLER A, VEČERIĆ-HALER Ž.Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review[J].Int J Mol Sci.2022,23(19):11307. [96] VOROBYEV P A,MOMOT A P,KRASNOVA L S,et al.Pathogenesis,diagnosis,prevention and treatment of disseminated intravascular coagulation syndrome in COVID-19 infection[J].Ter Arkh,2020,92(11):51-56. [97] ANAKLı İ,ERGIN ÖZCAN P,POLAT Ö,et al.Prognostic value of antithrombin levels in COVID-19 patients and impact of fresh frozen plasma treatment:a retrospective study[J].Turk J Haematol,2021,38(1):15-21. [98] MIR N,D'AMICO A,DASHER J,et al.Understanding the andromeda strain-The role of cytokine release,coagulopathy and antithrombin III in SARS-CoV2 critical illness[J].Blood Rev,2021,45:100731. [99] 中华医学会血液学分会血栓与止血学组.弥散性血管内凝血诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志,2012,33(11):978-979. [100] RHOADES R,LEONG R,KOPENITZ J,et al.Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO:advantages of a heparin anti-Xa-based titration strategy[J].Thromb Res,2021,203:1-4. [101] ASTON D,BESSER M,GODDARD B,et al.Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)[J].Clin Appl Thromb Hemost,2022,28:107602962211481. [102] 易星,袁晓华,白林,等.我国38家采供血机构新冠肺炎康复者恢复期血浆采集制备供应实践经验[J].临床输血与检验,2022,24(3):285-291. [103] THOMPSON M A,HENDERSON J P,SHAH P K,et al.Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19[J].JAMA Oncol,2021,7(8):1167-1175. [104] LI M,BECK E J,LAEYENDECKER O,et al.Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern[J].Blood Adv,2022,6(12):3678-3683. [105] 王月,喻剑虹,喻学华,等.670份新型冠状病毒肺炎康复者恢复期血浆检测结果分析[J].中国生物制品学杂志,2020,33(12):1409-1413. [106] FOCOSI D,FRANCHINI M,PIROFSKI L A,et al.COVID-19 convalescent plasma and clinical trials:understanding conflicting outcomes[J].Clin Microbiol Rev,2022,35(3):e0020021. [107] HUANG W,LI C Z,WANG Z Q,et al.Decreased serum albumin level indicates poor prognosis of COVID-19 patients:hepatic injury analysis from 2,623 hospitalized cases[J].Sci China Life Sci,2020,63(11):1678-1687. [108] TORRES-RUIZ J,PÉREZ-FRAGOSO A,MARAVILLAS-MONTERO J L,et al.Redefining COVID-19 severity and prognosis:the role of clinical and immunobiotypes[J].Front Immunol,2021,12:689966. [109] DENG X L,LIU B B,LI J H,et al.Blood biochemical characteristics of patients with coronavirus disease 2019 (COVID-19):a systemic review and meta-analysis[J].Clin Chem Lab Med CCLM,2020,58:1172-1181. [110] TIAN J B,YUAN X L,XIAO J,et al.Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan,China:a multicentre,retrospective,cohort study[J].Lancet Oncol,2020,21(7):893-903. [111] JAGDISH R K,MARAS J S,SARIN S K.Albumin in advanced liver diseases:the good and bad of a drug![J].Hepatology,2021,74(5):2848-2862. [112] HRYCIW N,JOANNIDIS M,HIREMATH S,et al.Intravenous albumin for mitigating hypotension and augmenting ultrafiltration during kidney replacement therapy[J].Clin J Am Soc Nephrol,2021,16(5):820-828. [113] WIEDERMANN C J.Moderator effect of hypoalbuminemia in volume resuscitation and plasma expansion with intravenous albumin solution[J].Int J Mol Sci,2022,23(22):14175. [114] MELIA D,POST B.Human albumin solutions in intensive care:a review[J].J Intensive Care Soc,2021,22(3):248-254. [115] SHAO Z Y,FENG Y W,ZHONG L,et al.Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19:a multicenter retrospective cohort study[J].Clin Transl Immunol,2020,9(10):e1192. [116] GALEOTTI C,KAVERI S V,BAYRY J.Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19)[J].Clin Transl Immunol,2020,9(10):e1198. [117] MARTINCIC Z,SKOPEC B,RENER K,et al.Severe immune thrombocytopenia in a critically ill COVID-19 patient[J].Int J Infect Dis,2020,99:269-271. [118] ZHU Y P,SHAMIE I,LEE J C,et al.Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C[J].J Clin Invest,2021,131(20):e147076. [119] CORNBLATH D R,VAN DOORN P A,HARTUNG H P,et al.Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy[J].Brain,2022,145(3):887-896. [120] KEDDIE S,EFTIMOV F,VAN DEN BERG L H,et al.Immunoglobulin for multifocal motor neuropathy[J].Cochrane Database Syst Rev,2022,1(1):CD004429. [121] ESMAEILZADEH H,ASKARISARVESTANI A,HOSSEINI N,et al.Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin[J].Clin Immunol,2021,230:108826. [122] KRETOWSKA-GRUNWALD A,KRAWCZUK-RYBAK M,SAWICKA-ZUKOWSKA M.Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process,pathogenesis,preventative measures and treatment[J].J Clin Med,2022,11(13):3571. [123] PENDERGRAST J,ARMALI C,CALLUM J,et al.A prospective observational study of the incidence,natural history,and risk factors for intravenous immunoglobulin-mediated hemolysis[J].Transfusion,2021,61(4):1053-1063. [124] LEVI M,TOH C H,THACHIL J,et al.Guidelines for the diagnosis and management of disseminated intravascular coagulation[J].Br J Haematol,2009,145(1):24-33. [125] LISMAN T,KLEISS S,PATEL V C,et al.In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis[J].Liver Int,2018,38(11):1988-1996. [126] AGARWAL S,LAYCOCK H C.The debate ROTEMs on - the utility of point-of-care testing and fibrinogen concentrate in postpartum haemorrhage[J].Anaesthesia,2020,75(9):1247-1251. [127] MCNAMARA H,KENYON C,SMITH R,et al.Four years' experience of a ROTEM®-guided algorithm for treatment of coagulopathy in obstetric haemorrhage[J].Anaesthesia,2019,74(8):984-991. [128] CASINI A,VON MACKENSEN S,SANTORO C,et al.Clinical phenotype,fibrinogen supplementation,and health-related quality of life in patients with afibrinogenemia[J].Blood,2021,137(22):3127-3136. [129] HARDY M,MICHAUX I,BULPA P,et al.Serial fibrin monomer and D-dimer plasma levels measurements can capture thrombotic complications in critically ill COVID-19 patients:a prospective observational study[J].Thromb Res,2023,221:69-72. [130] MILTIADES A,HOUCK P J,MONTELEONE M,et al.Insights into fibrinogen-mediated COVID-19 hypercoagubility in critically ill patients[J].J Neurosurg Anesthesiol,2022,34(1):136-140. [131] ROH D J,EISEMAN K,KIRSCH H,et al.Hypercoagulable viscoelastic blood clot characteristics in critically ill coronavirus disease 2019 patients and associations with thrombotic complications[J].J Trauma Acute Care Surg,2021,90(1):e7-e12. [132] CASINI A,DE MOERLOOSE P.How I treat dysfibrinogenemia[J].Blood,2021,138(21):2021-2030. [133] YASUNAGA H.Risk of authoritarianism:fibrinogen-transmitted hepatitis C in Japan[J].Lancet,2007,370(9604):2063-2067. [134] CURRY B,MUELLER S,MACLAREN R.The use of prothrombin complex concentrates:results of a nationwide survey of critical care pharmacists[J].J Pharm Pract,2022,35(2):197-204. [135] DOU X Q,LIU W,POON M C,et al.Patients with haemophilia A with inhibitors in China:a national real-world analysis and follow-up[J].Br J Haematol,2021,192(5):900-908. [136] MINGOT-CASTELLANO M E,GARCÍA-CANDEL F,BENÍTEZ-HIDALGO O,et al.Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A:BAHAS study[J].Eur J Haematol,2022,109(6):686-695. [137] WHITAKER C,MCKINNEY A,BOLLIG R,et al.Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients[J].J Thromb Thrombolysis,2022,53(4):861-867. [138] BOSWELL M R,STULAK J M,TCHANTCHALEISHVILI V,et al.Intraoperative prothrombin complex concentrate administration and outcomes in patients undergoing left ventricular assist device implantation[J].Artif Organs,2021,45(8):E223-E235. [139] COOKSEY G E,HAMILTON L A,MCMILLEN J C,et al.Impact of factor xa inhibitor reversal with prothrombin complex concentrate in patients with traumatic brain injuries[J].Neurocrit Care,2022,37(2):471-478. [140] CIVES T L,DOCAMPO M F,FERNÁNDEZ M T F,et al.Challenging treatment for refractory acquired haemophilia A complicated with severe severe acute respiratory coronavirus 2 infection[J].Blood Coagul Fibrinolysis,2022,33(6):342-347. [141] MIATECH J L,KANTAMANI D,STAGG M P.Management of acquired factor VIII inhibitors with NovoSeven and obizur[J].Cureus,2021,13(10):e19145. [142] SHAH E,ABRO C,ZAIDI F,et al.Doxycycline-induced acquired haemophilia A[J].BMJ Case Rep,2021,14(10):e244748. [143] DAS K,KESHAVA S,ANSARI S A,et al.Factor VIIa induces extracellular vesicles from the endothelium:a potential mechanism for its hemostatic effect[J].Blood,2021,137(24):3428-3442. [144] KJALKE M,KJELGAARD‐HANSEN M,ANDERSEN S,et al.Thrombin generation potential in the presence of concizumab and rFVIIa,APCC,rFVIII,or rFIX:In vitro and ex vivo analyses[J].J Thromb Haemost,2021,19(7):1687-1696. [145] CHUANSUMRIT A,SIRACHAINAN N,NATESIRINILKUL R,et al.Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes[J].Haemophilia,2021,27(1):69-80. [146] TIEDE A,FRIEDRICH U,STENMO C,et al.Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)[J].J Thromb Haemost,2011,9(6):1191-1199. [147] CROTEAU S E,NAKAR C,NEUFELD E J,et al.Safety and efficacy of recombinant factor VIIa by pediatric age cohort:reassessment of compassionate use and trial data supporting US label[J].Pediatr Blood Cancer,2016,63(10):1822-1828. [148] GOODNOUGH L T,SHANDER A S.Recombinant factor VIIa:safety and efficacy[J].Curr Opin Hematol,2007,14(5):504-509. [149] KIESSLING A H,NITSCH J,STROUHAL U,et al.Associated risk of recombinant activated factor VIIa application[J].Heart Surg Forum,2013,16(3):E132-E136. [150] 宋景春,王岗,张伟,等.新型冠状病毒肺炎重症患者相关凝血功能障碍诊疗专家共识[J].解放军医学杂志,2020,45(4):335-344. [151] 国家卫生健康委员会.输血反应分类:WS/T622-2018[S/OL].(2018-09-26).http://www.nhc.gov.cn/wjw/s9493/201901/d0c123125a9b4b459ed880a2bc612f78.shtml. [152] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会肺血管疾病学组,中国肺栓塞救治团队(PERT)联盟.急性肺栓塞多学科团队救治中国专家共识[J].中华心血管病杂志,2022,50(1):25-35. [153] 中华医学会心血管病学分会肺血管病学组.急性肺栓塞诊断与治疗中国专家共识(2015)[J].中华心血管病杂志,2016,44(3):197-211. |
| [1] | 中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血（TDT）患者临床输血中国专家共识[J]. 临床输血与检验, 2023, 25(2): 163-169. |
| [2] | 治疗性单采过程管理与质量控制专家共识编写组. 治疗性单采过程管理与质量控制专家共识[J]. 临床输血与检验, 2023, 25(1): 1-9. |
| [3] | 杜亚丽, 张蓉, 王燕菊, 陈丽, 蒋学兵. 年轻血浆抗衰老作用及其机制研究进展*[J]. 临床输血与检验, 2023, 25(1): 137-142. |
| [4] | 国防科技创新特区重点项目专家组. 冰冻红细胞质量评价指标专家共识[J]. 临床输血与检验, 2022, 24(6): 681-686. |
| [5] | 中国输血协会临床输血学专业委员会. 非心脏外科围手术期患者血液管理专家共识（2022版）[J]. 临床输血与检验, 2022, 24(5): 545-553. |
| [6] | 康澜, 李世林, 杨春晖. 血液成分中病原体灭活技术及其研究进展[J]. 临床输血与检验, 2022, 24(4): 521-527. |
| [7] | 中国输血协会人类组织抗原专业委员会, 中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识*[J]. 临床输血与检验, 2022, 24(3): 273-278. |
| [8] | 中国人体健康科技促进会妇科内分泌和生育力促进分会, 中国女医师协会输血专业委员会. 自体富血小板纤维蛋白（PRF）治疗宫腔粘连专家共识[J]. 临床输血与检验, 2022, 24(3): 279-284. |
| [9] | 北京医学会输血医学分会, 北京医师协会输血专业专家委员会. 中国输血医师规范化培训实施方案专家共识[J]. 临床输血与检验, 2021, 23(1): 1-5. |
| [10] | 中国输血协会免疫血液学专业委员会. 胎儿新生儿溶血病实验室检测专家共识*[J]. 临床输血与检验, 2021, 23(1): 20-24. |
| [11] | 中国医师协会输血科医师分会. 医疗机构中乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒(1+2型)核酸检测策略专家共识[J]. 临床输血与检验, 2020, 22(6): 561-564. |
| [12] | 李宏洋, 杨佶军, 成鹏, 刘铁梅. 精准化输血标本定位信息系统的应用*[J]. 临床输血与检验, 2020, 22(3): 282-284. |
| [13] | 魏亚明, 桂嵘, 王秋实, 刘志伟. 血小板抗体检测专家共识[J]. 临床输血与检验, 2020, 22(1): 1-5. |
| [14] | 郑艳梅, 高健, 柴声江. 襄阳地区临床用血工作调查分析与思考[J]. 临床输血与检验, 2019, 21(5): 471-473. |
| [15] | 张春荣, 吴敏, 杨红梅, 张华. 血液成分集中化质量检查的可行性探讨[J]. 临床输血与检验, 2018, 20(2): 212-215. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
